NEWBORN SCREENING OF INFANTS AND NEWBORNS WITH CONGENITAL HYPOTHYROIDISM
Associate Professor Michelle Jack
Clinical Practice & Co-Lead Doctor of Medicine
Bond University, Queensland, Australia
RESEARCHER PROFILE
Filmed in Robina, Queensland | July 2024
Michelle Jack is Associate Professor of Clinical Practice, Faculty of Health Sciences & Medicine at Bond University, QLD and co-Head of Paediatrics and a Paediatric Endocrinologist at Lismore Base Hospital in NSW. She graduated from Medicine at the University of Queensland with first class honours and the University Gold Medal and has a PhD in hyperinsulinism from the University of QLD. She has postgraduate qualifications in higher education and is a fellow of the higher education academy.
Assoc Prof Jack is an experienced leader and practitioner in the healthcare, research and higher education sectors. Career highlights include: Head of Department Paediatric Endocrinology, Royal North Shore Hospital; Academic Lead Education & Partnerships, University Centre for Rural Health, University of Sydney; Head of the Beta Cell Laboratory, Kolling Institute; Chair Australasian Paediatric Endocrine Group scientific program organising committee and Co-Chair international scientific program organising committees; Chair Northern Sydney Adolescent Committee; International Research Fellowship, Juvenile Diabetes Research Foundation, Head of Research, Impact Institute.
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
Integrated Oral Health Care
Dr Ajesh George is a Professor of Interprofessional Oral Health in the School of Nursing and Midwifery, Western Sydney University (WSU) and Honorary Professor in the School of Dentistry at The University of Sydney. He is a dentist with extensive experience in integrated oral health care and is a renowned expert globally in providing oral health training to non-dental professionals and translating oral health guidelines into their practice. Dr George is also the Director and Co-founder of the “Australian Centre for Integration of Oral Health” (ACIOH) which is a leading national research centre led by WSU in collaboration with various partners including universities, health services and professional organisations.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
